X
Alnylam hopes for 2018 filing for RNAi liver disease drug
https://pharmaphorum.com/news/alnylam-hopes-2018-filing-rnai-liver-disease-drug/
hepatology
Novo Nordisk board member quits over NASH conflict of interest
Mary Szela has quit to avoid a conflict of interest.
Can Gilead find another Pharmasset in 2017?
Company needs to make acquisition to grow, admits CEO.